Market LIVE
Published markets; coverage varies by country
Product profile · United States

RELISTOR

 ·  Patent Litigation & Settlement History ↓

IngredientMETHYLNALTREXONE BROMIDE
Application typeNDA
Application021964
Product002
Dosage formSOLUTION
RouteSUBCUTANEOUS
Strength8MG/0.4ML (8MG/0.4ML)
Approval date2010-09-27
Marketing statusPrescription
Status event—
ApplicantSALIX PHARMS
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2024-08-26
Status event—

Final ANDA candidate 208112/001 on 2024-08-26. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
123035922027-08-03DP/U U-4197———
———
123035922027-08-03DP/U U-4198———
———
84206632029-09-30U U-1185———
———
88224902029-09-30DP/U U-1185———
———
91801252029-09-30DP/U U-1185———
———
94924452029-09-30DP/U U-1185———
———
82474252030-12-31U U-1185———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208112 / 001FINAL_APPROVAL · FINAL_APPROVED2024-08-26—ACTAVIS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208112 / 001ACTAVIS LLCFINAL_APPROVAL · FINAL_APPROVED2024-08-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.